Department of Urology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
Department of Urology, University of Health Sciences, Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey.
Prog Urol. 2023 Jul;33(7):393-400. doi: 10.1016/j.purol.2023.02.010. Epub 2023 Mar 21.
We aimed to determine the effectiveness of Nintedanib treatment, which has known antifibrotic effect, in preventing fibrosis after urethral trauma.
Twenty-three adult Sprague-Dawley rats were divided randomly into 3 different groups: Sham, Urethral injury group (UI) and Urethral injury+ Nintedanib (UI+N). The urethral injury model was made with a pediatric urethrotome knife. Nintedanib was administered at a dose of 50mg/kg by oral gavage for 14 days at the same time every day. After 14 days of treatment, all rats were performed penectomy under general anesthesia. Urethral tissue was evaluated histopathologically (congestion, inflammatory cell infiltration and spongiofibrosis) and immunohistochemically (transforming growth factor (TBF) Beta-1 and vascular endothelial growth factor receptor 2 (VEBFR2)).
Histopathological findings: Group UI had higher scores in all categories (congestion, inflammatory cell infiltration, and spongiofibrosis), followed by Group UI+N and Group Sham, respectively. A statistically significant difference was found between Group UI and Group UI+N in terms of the scores of histopathological parameters (p<0.05). Immunohistochemical findings: Group UI had higher scores in both categories, followed by Group UI+N and Group Sham, respectively. A statistically significant difference was found between Group UI and Group UI+N in TGF Beta-1 and VEGF scores (p<0.05).
We found that Nintedanib administration after urethral trauma reduced inflammation and fibrosis histologically and immunohistochemically. The positive effect of Nintedanib on inflammation and fibrosis after urethral trauma reported in this animal study is encouraging for a potential clinical human application.
我们旨在确定尼达尼布(一种已知的抗纤维化药物)治疗在预防尿道创伤后纤维化的有效性。
将 23 只成年 Sprague-Dawley 大鼠随机分为 3 组:假手术组(Sham)、尿道损伤组(UI)和尿道损伤+尼达尼布组(UI+N)。使用小儿尿道扩张器刀制作尿道损伤模型。尼达尼布以 50mg/kg 的剂量通过口服灌胃给药,每天同一时间给药 14 天。治疗 14 天后,所有大鼠均在全身麻醉下进行阴茎切除术。通过组织病理学(充血、炎症细胞浸润和海绵纤维化)和免疫组织化学(转化生长因子(TGF)β-1 和血管内皮生长因子受体 2(VEGF-R2))评估尿道组织。
组织病理学发现:UI 组在所有分类(充血、炎症细胞浸润和海绵纤维化)中的评分均较高,其次是 UI+N 组和 Sham 组。UI 组和 UI+N 组之间在组织病理学参数评分方面存在统计学差异(p<0.05)。免疫组织化学发现:UI 组在两个分类中的评分均较高,其次是 UI+N 组和 Sham 组。UI 组和 UI+N 组在 TGFβ-1 和 VEGF 评分方面存在统计学差异(p<0.05)。
我们发现尿道创伤后给予尼达尼布治疗可在组织学和免疫组织化学上减轻炎症和纤维化。本动物研究报告的尼达尼布对尿道创伤后炎症和纤维化的积极作用令人鼓舞,有望在临床上得到应用。